Justin T. Wahlstrom

Hematology | Oncology

550 16th St Fl 4
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.

Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.

Journal: Blood advances

Published: October 24, 2023

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 06, 2023

Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.

Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.

Journal: Transplantation and cellular therapy

Published: June 14, 2022

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD.

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD.

Journal: Journal of clinical immunology

Published: January 18, 2021

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.

Journal: Blood

Published: September 05, 2019

Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.

Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.

Journal: Blood

Published: February 18, 2019

Neurologic event-free survival demonstrates a benefit for SCID patients diagnosed by newborn screening.

Neurologic event-free survival demonstrates a benefit for SCID patients diagnosed by newborn screening.

Journal: Blood advances

Published: July 22, 2017

Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID.

Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID.

Journal: Bone marrow transplantation

Published: April 25, 2017

Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.

Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: April 19, 2017

Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.

Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.

Journal: Bone marrow transplantation

Published: April 11, 2017

Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia.

Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia.

Journal: Pediatric blood & cancer

Published: November 14, 2016

Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab.

Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab.

Journal: Bone marrow transplantation

Published: June 09, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026